Compare J M Smucker Co (SJM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J M Smucker Co vs BIO-TECHNE Corp — how do they compare? J M Smucker Co trades at $117.46 (market cap $12.84B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: J M Smucker Co and BIO-TECHNE Corp are close in size by market cap, and J M Smucker Co pays the higher dividend (3.73%). Which is the better fit depends on your goals.
| SJM | TECH | |
|---|---|---|
Market Cap | $12.84B | $11.24B |
Sector | Consumer Staples | Health |
52-Week High | $126.35 | $72.29 |
52-Week Low | $89.53 | $43.31 |
Enterprise Value | $19.87B | $11.32B |
Dividend Yield | 3.73% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SJM trades at $120.16, up 1.14% today, with a bullish technical signal and strong analyst support. Recent earnings beat expectations in Q4 2025 and Q1 2026, though Q2 2026 results are pending. The company maintains a solid dividend track record, raising payouts for 25 consecutive years. Revenue growth is stable, but negative net income and ROE highlight profitability challenges amid high debt levels.
Outlook is cautiously optimistic with a consensus price target of $125.11 offering 4% upside. Key risks include persistent negative margins and elevated leverage, while opportunities lie in cost controls and brand strength. Investors should weigh dividend reliability against earnings volatility in the consumer staples sector.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J M Smucker Co
J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.
Read more on SJM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
